P2Y12 receptor protein in cortical gray matter lesions in multiple sclerosis

Cerebral Cortex

Volumn 20, Issue 6, 2010, Pages 1263-1273

  Amadio, Susanna ^a   Montilli, Cinzia ^a   Magliozzi, Roberta ^b   Bernardi, Giorgio ^a   Reynolds, Richard ^b   Volonté, Cinzia ^a,c  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CNR   (Italy)

Author keywords

Astrocyte; Demyelination; Extracellular ATP; Oligodendrocyte; Purinergic receptor

Indexed keywords

MYELIN; PURINERGIC P2X1 RECEPTOR; PURINERGIC P2X2 RECEPTOR; PURINERGIC P2X3 RECEPTOR; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X5 RECEPTOR; PURINERGIC P2X6 RECEPTOR; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y11 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y13 RECEPTOR; PURINERGIC P2Y2 RECEPTOR; PURINERGIC P2Y4 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; BIOLOGICAL MARKER; P2RY12 PROTEIN, HUMAN; PURINERGIC P2 RECEPTOR;

ADULT; AGED; ARTICLE; ASTROCYTE; BRAIN CORTEX; CADAVER; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DEMYELINATION; FEMALE; GRAY MATTER; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOREACTIVITY; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION; WESTERN BLOTTING; WHITE MATTER; MALE; METABOLISM; MIDDLE AGED; MYELIN SHEATH; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ASTROCYTES; BIOLOGICAL MARKERS; CEREBRAL CORTEX; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN SHEATH; RECEPTORS, PURINERGIC P2; RECEPTORS, PURINERGIC P2Y12;

EID: 77952870400     PISSN: 10473211     EISSN: 14602199     Source Type: Journal    
DOI: 10.1093/cercor/bhp193     Document Type: Article

References (78)

1. Agresti C, Meomartini ME, Amadio S, Ambrosini E, Serafini B, Franchini L, Volonte C, Aloisi F, Visentin S. 2005. Metabotropic P2 receptor activation regulates oligodendrocyte progenitor migration and development. Glia. 50:132-144.
2. Agresti C, Meomartini ME, Amadio S, Ambrosini E, Volonte C, Aloisi F, Visentin S. 2005. ATP regulates oligodendrocyte progenitor migration, proliferation, and differentiation: involvement of metab-otropic P2 receptors. Brain Res Brain Res Rev. 48:157-165.
3. Amadio S, Tramini G, Martorana A, Viscomi MT, Sancesario G, Bernardi G, Volonte C. 2006. Oligodendrocytes express P2Y12 metabotropic receptor in adult rat brain. Neuroscience. 141: 1171-1180.
4. Apolloni S, Montilli C, Finocchi P, Amadio S. 2009. Membrane compartments and purinergic signaling: P2X receptors in neurode-generative and neuroinflammatory events. FEBS J. 276:354-364.
5. Bernstein M, Lyons SA, Moller T, Kettenmann H. 1996. Receptor-mediated calcium signalling in glial cells from mouse corpus callosum slices. J Neurosci Res. 46:152-163.
6. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. 2000. Acute axonal injury in multiple sclerosis. Correlation with de-myelination and inflammation. Brain. 123:1174-1183.
7. Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. 2001. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology. 57:1248-1252.
8. Block ML, Hong JS. 2005. Microglia and inflammation-mediated neuro-degeneration: multiple triggers with a common mechanism. Prog Neurobiol. 76:77-98.
9. Bo L, Geurts JJ, Mork SJ, van der Valk P. 2006. Grey matter pathology in multiple sclerosis. Acta Neurol Scand. 183:48-50.
10. Bø L, Vedeler CA, Nyland HI, Trapp BD, Mørk SJ. 2003. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol. 62:723-732.
11. Brownell B, Hughes JT. 1962. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry. 25:315-320.
12. Burnstock G. 2006. Historical review: ATP as a neurotransmitter. Trends Pharmacol Sci. 27:166-176.
13. Burnstock G. 2007a. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev. 87:659-797.
14. Burnstock G. 2007b. Purine and pyrimidine receptors. Cell Mol Life Sci. 64:1471-1483.
15. Burnstock G. 2008. Unresolved issues and controversies in purinergic signalling. J Physiol. 586:3307-3312.
16. Burnstock G, Abbracchio MP, Lewis S, Verkhratsky A, Zimmermann H. 2009. The expanding field of purinergic signalling. Trends Neurosci. 32:1.
17. Cattaneo M. 2007. Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Rev Cardiovasc Ther. 5:45-55.
18. Colombo JA, Quinn B, Puissant V. 2002. Disruption of astroglial interlaminar processes in Alzheimer's disease. Brain Res Bull. 58:235-242.
19. Compston A, Coles A. 2002. Multiple sclerosis. Lancet. 359:1221-1231
20. Erratum in: Lancet. 2002 Aug 24; 360(9333): 648.
21. Dawson J. 1916. The histology of disseminated sclerosis. Trans R Soc Edin. 50:517-740.
22. Fields RD, Burnstock G. 2006. Purinergic signalling in neuron-glia interactions. Nat Rev Neurosci. 7:423-436.
23. Fischer W, Krugel U. 2007. P2Y receptors: focus on structural, pharmacological and functional aspects in the brain. Curr Med Chem. 14:2429-2455.
24. Franke H, Krugel U, Illes P. 2006. P2 receptors and neuronal injury. Pflugers Arch. 452:622-644.
25. Franke H, Krugel U, Schmidt R, Grosche J, Reichenbach A, Illes P. 2001. P2 receptor-types involved in astrogliosis in vivo. Br J Pharmacol. 134:1180-1189.
26. Gay F. 2007. Activated microglia in primary MS lesions: defenders or aggressors? Int MS J. 14:78-83.
27. Geurts JJ. 2008. Is progressive multiple sclerosis a gray matter disease? Ann Neurol. 64:230-232.
28. Geurts JJ, Barkhof F. 2008. Grey matter pathology in multiple sclerosis. Lancet Neurol. 7:841-851.
29. Gilmore CP, Donaldson I, Bo L, Owens T, Lowe JS, Evangelou N. 2009. Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J Neurol Neurosurg Psychiatry. 80:182-187.
30. Gobin SJ, Montagne L, Van Zutphen M, Van Der Valk P, Van Den Elsen PJ, De Groot CJ. 2001. Upregulation of transcription factors controlling MHC expression in multiple sclerosis lesions. Glia. 36:68-77.
31. Goncxalves J, Queiroz G. 2008. Presynaptic adenosine and P2Y receptors. Handb Exp Pharmacol. 184:339-372.
32. Hauser SL, Oksenberg JR. 2006. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 52:61-76.
33. He M, McCarthy KD. 1994. Oligodendroglial signal transduction systems are developmentally regulated. J Neurochem. 63:501-508.
34. He F, Sun YE. 2007. Glial cells more than support cells? Int J Biochem Cell Biol. 39:661-665.
35. Holley JE, Gveric D, Newcombe J, Cuzner ML, Gutowski NJ. 2003. Astrocyte characterization in the multiple sclerosis glial scar. Neuropathol Appl Neurobiol. 29:434-444.
36. Inoue K, Koizumi S, Tsuda M. 2007. The role of nucleotides in the neuron-glia communication responsible for the brain functions. J Neurochem. 102:1447-1458.
37. Irvine KA, Blakemore WF. 2008. Remyelination protects axons from demyelination-associated axon degeneration. Brain. 131: 1464-1477.
38. Ishibashi T, Dakin K, Stevens B, Lee P, Kozlov S, Stewart C, Fields R. 2006. Astrocytes promote myelination in response to electrical impulses. Neuron. 49:823-832.
39. James G, Butt AM. 2001. P2X and P2Y purinoreceptors mediate ATP-evoked calcium signalling in optic nerve glia in situ. Cell Calcium. 30:251-259.
40. James G, Butt AM. 2002. P2Y and P2X purinoceptor mediated Ca2+ signalling in glial cell pathology in the central nervous system. Eur J Pharmacol. 447:247-260.
41. Kettenmann H, Verkhratsky A. 2008. Neuroglia: the 150 years after. Trends Neurosci. 31:653-659.
42. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. 1999. Cortical lesions in multiple sclerosis. Brain. 122:17-26.
43. Koles L, Furst S, Illes P. 2007. Purine ionotropic (P2X) receptors. Curr Pharm Des. 13:2368-2384.
44. 2+ release from InsP3-sensitive internal stores in mammalian oligodendrocytes. J Physiol. 483:41-57.
45. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H. 2005. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 128:2705-2712.
46. Laitinen JT, Uri A, Raidaru G, Miettinen R. 2001. [(35)S]GTPgammaS autoradiography reveals a wide distribution of G(i/o)-linked ADP receptors in the nervous system: close similarities with the platelet P2Y(ADP) receptor. J Neurochem. 77:505-518.
47. Lassmann H. 1998. Neuropathology in multiple sclerosis: new concepts. Mult Scler. 4:93-98.
48. Lassmann H. 2007. Cortical, subcortical and spinal alterations in neuroimmunological diseases. J Neurol. 254(II):15-17.
49. Erratum in: J Neurol. 2008; 255(2): 309-310.
50. Lassmann H, Lucchinetti CF. 2008. Cortical demyelination in CNS inflammatory demyelinating diseases. Neurology. 70:332-333.
51. Lumsden CE. 1970. The neuropathology of multiple sclerosis. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology. Multiple sclerosis and other demyelinating diseases. Amsterdam (Netherlands): North Holland. p. 217-309.
52. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F. 2007. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 130:1089-1104.
53. Matute C. 2008. P2X7 receptors in oligodendrocytes: a novel target for neuroprotection. Mol Neurobiol. 38:123-128.
54. Matute C, Torre I, Perez-Cerda F, Perez-Samart?n A, Alberdi E, Etxebarria E, Arranz AM, Ravid R, Rodr?guez-Antiguedad A, Sanchez-Gomez M, et al. 2007. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci. 27:9525-9533.
55. Michelson AD. 2008. P2Y12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol. 28:s33-s38.
56. Moll NM, Rietsch AM, Ransohoff AJ, Cossoy MB, Huang D, Eichler FS, Trapp BD, Ransohoff RM. 2008. Cortical demyelination in PML and MS: similarities and differences. Neurology. 70:336-343.
57. Moran-Jimenez MJ, Matute C. 2000. Immunohistochemical localization of the P2Y(1) purinergic receptor in neurons and glial cells of the central nervous system. Brain Res Mol Brain Res. 78:50-58.
58. Muzio L, Martino G, Furlan R. 2007. Multifaceted aspects of inflammation in multiple sclerosis: the role of microglia. J Neuro-immunol. 191:39-44.
59. Nasu-Tada K, Koizumi S, Inoue K. 2005. Involvement of beta1 integrin in microglial chemotaxis and proliferation on fibronectin: different regulations by ADP through PKA. Glia. 52:98-107.
60. Oberheim NA, Wang X, Goldman S, Nedergaard M. 2006. Astrocytic complexity distinguishes the human brain. Trends Neurosci. 29:547-553.
61. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. 2001. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 50:389-400.
62. Peterson JW, Trapp BD. 2005. Neuropathobiology of multiple sclerosis. Neurol Clin. 23:107-129.
63. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. 2007. Gray matter involvement in multiple sclerosis. Neurology. 68:634-642.
64. Quarles RH. 2002. Myelin sheaths: glycoproteins involved in their formation, maintenance and degeneration. Cell Mol Life Sci. 59:1851-1871.
65. Sanders P, De Keyser J. 2007. Janus faces of microglia in multiple sclerosis. Brain Res Rev. 54:274-285.
66. Stadelmann C, Bruck W. 2008. Interplay between mechanisms of damage and repair in multiple sclerosis. J Neurol. 255(Suppl. 1):12-18.
67. Stadelmann C, Albert M, Wegner C, Bruck W. 2008. Cortical pathology in multiple sclerosis. Curr Opin Neurol. 21:229-234.
68. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. 1998. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 338:278-285.
69. Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, Cavalla P. 2005. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol. 64:1101-1107.
70. Volonte C, Amadio S, D'Ambrosi N. 2008. Receptor webs: can the chunking theory tell us more about it? Brain Res Rev. 59:1-8.
71. Volonte C, Amadio S, Cavaliere F, D'Ambrosi N, Vacca F, Bernardi G. 2003. Extracellular ATP and neurodegeneration. Curr Drug Targets CNS Neurol Disord. 2:403-412
72. Volonte C, Amadio S, D'Ambrosi N, Colpi M, Burnstock G. 2006.P2receptor web: complexity and fine-tuning. Pharmacol Ther. 112:264-280.
73. Volonte C, D'Ambrosi N. 2009. Membrane compartments and puriner-gic signaling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. FEBS J. 276:318-329.
74. Volonte C, D'Ambrosi N, Amadio S. 2008. Protein cooperation: from neurons to networks. Prog Neurobiol. 86:61-71.
75. Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. 2006. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology. 67:960-967.
76. Williams A, Piaton G, Lubetzki C. 2007. Astrocytes-friends or foes in multiple sclerosis? Glia. 55:1300-1312.
77. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, Banati RR, Anand P. 2006. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 6:12.
78. Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Bruck W, Hartung HP, Stadelmann C, Hemmer B. 2006. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA. 103:19057-19062.